- Trials with a EudraCT protocol (154)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
154 result(s) found for: Influenza Vaccines AND Influenza Virus.
Displaying page 6 of 8.
EudraCT Number: 2005-000659-14 | Sponsor Protocol Number: V78P3S | Start Date*: 2005-05-09 |
Sponsor Name:Chiron Vaccines Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2005-2006, when administered... | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002063-27 | Sponsor Protocol Number: V78P5S | Start Date*: 2007-06-28 |
Sponsor Name:Novartis Vaccines and Diagnostics Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2007-2008, when Adm... | ||
Medical condition: Prophylaxis of Influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000787-88 | Sponsor Protocol Number: V78P4S | Start Date*: 2006-06-30 |
Sponsor Name:Chiron Vaccines Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, when Administered... | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005185-30 | Sponsor Protocol Number: V112_04 | Start Date*: 2014-12-05 |
Sponsor Name:Novartis Vaccines and Diagnostics | ||
Full Title: A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derive... | ||
Medical condition: Prophylaxis of A(H1N1) 2009 Pandemic Influenza | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-005682-13 | Sponsor Protocol Number: 76061 | Start Date*: 2021-04-22 |
Sponsor Name:Radboudumc | ||
Full Title: Exploratory study into age-related immunological differences related to immunogenicity in influenza vaccination and herpes zoster vaccination | ||
Medical condition: Influenza Herpes Zoster | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013858-32 | Sponsor Protocol Number: GPF09 | Start Date*: 2009-09-14 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 ... | ||
Medical condition: Preventive vaccination in healthy subjects aged 6 to 35 months against infection with S-OIV (Swine Origin Influenza Virus) A/California/7/2009 (H1N1) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000101-54 | Sponsor Protocol Number: 8162 | Start Date*: 2006-02-10 |
Sponsor Name:University Hospitals Leicester, Leicester General Hospital | ||
Full Title: A randomized, observer-blind, dose-ranging, single-centre, study to evaluate the safety, tolerability and immunogenicity of adjuvanted and non-adjuvanted influenza A/Hong Kong/1073/99 (H9N2) vaccin... | ||
Medical condition: Vaccine study to assess the safety and immunogenicity of whole virus, alum-adjuvanted whole virus and virosomal A/HongKong/1073/99 (H9N2) vaccine in healthy adult volunteers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003620-16 | Sponsor Protocol Number: IIV-465 | Start Date*: 2021-05-27 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Vaccine immunogenicity in Dutch frail versus non-frail older individuals (participating in the Doetinchem Cohort study) | ||
Medical condition: Older adults 73-79 years of age, birth cohorts year 1941-1947, still participating in round 6 of the Doetinchem Cohort Study. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002649-35 | Sponsor Protocol Number: M78P2 | Start Date*: 2006-08-29 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase IV, Single-Centre, Observer-Blind, Controlled, Randomized Study to Compare the Safety and Immunogenicity of Fluvirin® to Influvac® Administered to Healthy Children 3 to 12 Years of Age. | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013672-45 | Sponsor Protocol Number: V111_03 | Start Date*: 2009-08-27 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and non-Adjuvanted Egg-derived, Inactivated Novel Swine... | ||
Medical condition: Pandemic influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005075-88 | Sponsor Protocol Number: V110_08 | Start Date*: 2014-12-15 |
Sponsor Name:Novartis Pharma K.K | ||
Full Title: A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1... | ||
Medical condition: Prophylaxis of A (H1N1) 2009 Swine Origin Pandemic Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004248-36 | Sponsor Protocol Number: V70_50 | Start Date*: 2014-10-14 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-013639-39 | Sponsor Protocol Number: V110_03 | Start Date*: 2009-07-29 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine ... | ||
Medical condition: Pandemic influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005032-26 | Sponsor Protocol Number: 106445, | Start Date*: 2015-06-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase III, open, randomized, controlled, multi-centre study to demonstrate the non-inferiority of the meningococcal serogroup C and the Haemophilus influenzae type b immune response of GlaxoSmith... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for primary immunization against meningococcal serogroup C and booster immunization against Haemophilus influenzae type b diseases of healthy children aged 12-18 months) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003041-35 | Sponsor Protocol Number: TJB2224 | Start Date*: 2022-10-20 |
Sponsor Name:CHU de Liège | ||
Full Title: Impact of the immune system on response to inactivated influenza vaccine (IIV) in allogeneic stem cell recipients | ||
Medical condition: Allogeneic hematopoietic stem cell recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005477-22 | Sponsor Protocol Number: 107495 | Start Date*: 2007-01-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H... | ||
Medical condition: Immunization against influenza disease during pandemic in subjects aged 18 to 60 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000115-28 | Sponsor Protocol Number: 109817 | Start Date*: 2007-07-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in a... | ||
Medical condition: Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Preven... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004123-16 | Sponsor Protocol Number: 2019nCoV-302 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Novavax, Inc. | |||||||||||||
Full Title: A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ... | |||||||||||||
Medical condition: Prevention of COVID-19 caused by SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002727-15 | Sponsor Protocol Number: 114174 | Start Date*: 2015-06-22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013931-39 | Sponsor Protocol Number: 113525 | Start Date*: 2009-09-08 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, observer-blind, randomized study to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccine containing... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza and seasonal influenza (2009-2010) in male and female subjects aged 61 years and older. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
